89BIO (ETNB) Expected to Announce Quarterly Earnings on Monday

Key Points

• 89BIO is expected to release its Q2 2025 earnings on August 4th, anticipating earnings of ($0.49) per share.
• The company reported a previous EPS of ($0.49), slightly beating analysts' estimates, and has an average PE ratio of -2.84 with a market cap of $1.40 billion.
• Insider trading activity includes Quoc Le-Nguyen selling 10,461 shares, revealing a 3.27% decrease in ownership, while institutional investors like Goldman Sachs have increased their holdings significantly.

89BIO (NASDAQ:ETNB - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 4th. Analysts expect 89BIO to post earnings of ($0.49) per share for the quarter.

89BIO (NASDAQ:ETNB - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.01. During the same quarter last year, the firm posted ($0.54) EPS. On average, analysts expect 89BIO to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

89BIO Stock Performance

ETNB stock traded down $0.06 during trading hours on Monday, reaching $9.53. The stock had a trading volume of 933,403 shares, compared to its average volume of 1,325,126. The stock has a market capitalization of $1.39 billion, a PE ratio of -2.82 and a beta of 1.28. The company has a debt-to-equity ratio of 0.06, a current ratio of 18.03 and a quick ratio of 18.03. The stock has a 50-day simple moving average of $10.03 and a 200 day simple moving average of $8.75. 89BIO has a fifty-two week low of $4.16 and a fifty-two week high of $11.84.

Insider Buying and Selling

In related news, insider Quoc Le-Nguyen sold 10,461 shares of the firm's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $11.02, for a total transaction of $115,280.22. Following the transaction, the insider directly owned 309,364 shares of the company's stock, valued at approximately $3,409,191.28. This trade represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.80% of the company's stock.

Hedge Funds Weigh In On 89BIO

Several hedge funds have recently bought and sold shares of ETNB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in 89BIO by 42.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,856 shares of the company's stock valued at $535,000 after buying an additional 21,702 shares during the period. AQR Capital Management LLC acquired a new stake in shares of 89BIO in the 1st quarter valued at approximately $583,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of 89BIO by 50.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,798 shares of the company's stock valued at $1,954,000 after purchasing an additional 90,107 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of 89BIO by 23.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 995,449 shares of the company's stock valued at $7,237,000 after purchasing an additional 188,367 shares in the last quarter.

Wall Street Analyst Weigh In

ETNB has been the subject of a number of recent analyst reports. Cantor Fitzgerald upgraded shares of 89BIO to a "strong-buy" rating in a research note on Wednesday, April 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of 89BIO in a research report on Saturday, July 12th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, 89BIO currently has a consensus rating of "Buy" and a consensus price target of $26.43.

About 89BIO

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.